Kalaris Therapeutics posts smaller-than-expected Q1 net loss

Kalaris Therapeutics

12/05/2026 13:09

Overview

US biopharmaceutical firm's Q1 net loss beat analyst expectations

Cash and equivalents expected to fund operations into Q4 2027

Outlook

Company expects cash to fund operations into Q4 2027 and through key clinical milestones

Result Drivers

HIGHER CLINICAL SPENDING - Increased research and development expenses were driven by higher CRO and clinical costs as the company expanded investigational sites and patient enrollment

PIPELINE PROGRESS - Completion of new manufacturing batch and ongoing patient screening for Phase 1b/2 study contributed to operating expenses

Company press release: ID:nGNX4PS2Df

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$10.86 mln
-$11.70 mln (5 Analysts)
Q1 Operating Income
Slight Miss*
-$11.83 mln
-$11.80 mln (3 Analysts)
Q1 Operating Expenses
$11.83 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $19.00, about 301.7% above its May 11 closing price of $4.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)